



Quality of Life in Patients Treated with Percutaneous Laser Ablation for Non-Functioning Benign Thyroid Nodules: A Prospective Single-Center Study

Silvia Oddo, MD¹, Edineia Felix, MD¹, Michele Mussap, MD², Massimo Giusti, MD¹

¹Endocrinology Unit and ²Laboratory Medicine Service Unit, IRCCS San Martino University Hospital-IST, Largo Rosanna Benzi, n°10, I-16132 Genoa, Italy

Objective: While many studies have reported that laser ablation (LA) for benign non-functioning thyroid nodules is efficacious in reducing nodular volume and neck symptoms, none have described changes in quality of life (QoL). The purpose of this study was to report post-LA changes in QoL in our cohort of patients.

Materials and Methods: Fourteen patients with benign thyroid nodules were involved in a prospective, single-center study and underwent a single session of LA. We evaluated the following: changes in nodule volume, thyroid function, and autoimmunity; adverse events during and after LA; changes in neck discomfort by means of a visual analogic scale (VAS) at one week and 1, 3, 6, and 12 months; and changes in QoL through the 13-scale Thyroid-specific Patient Reported Outcome (ThyPRO) questionnaire at 1, 3, 6, and 12 months. ThyPRO is a validated questionnaire for thyroid diseases, which consists of 13 scales with multiple-choice answers. They investigate several aspects of life that may be impaired by goiter-related compression symptoms, by esthetic alterations and by hypo- or hyperthyroidism.

Results: Nodule volume decrease was $-37 \pm 23\%$, $-55 \pm 22\%$, $-53 \pm 25\%$, $-58 \pm 25\%$ ($p < 0.01$ vs. baseline) at the first, third, sixth, and twelfth month, respectively. No hypothyroidism or positivization of autoimmunity was observed. There were no major complications during or after LA. After LA, VAS scores improved significantly from 1 week onwards in 100% of patients, while a significant improvement was seen in the goiter symptoms score after one month, and in the general score and mean values of ThyPRO after six months. Scores on the other ThyPRO scales did not change significantly.

Conclusion: Laser ablation is safe and effective in reducing nodule volume and neck symptoms; this is confirmed by improvements in the goiter scale, general score, and mean values of ThyPRO and in the VAS score.

Keywords: *Laser ablation; Quality of life; Benign thyroid nodule; Thyroid; Laser; Thyroid nodule*

INTRODUCTION

Since 2010, the American Association of Clinical Endocrinologists-Associazione Medici Endocrinologi-European Thyroid Association (AACE-AME-ETA) guidelines

Received November 17, 2016; accepted after revision July 6, 2017.

Corresponding author: Silvia Oddo, MD, Endocrinology Unit, IRCCS AOU San Martino University-IST, Largo Rosanna Benzi, n°10, I-16132 Genoa, Italy.

• Tel: 39-010-3537958 • Fax: 39-010-3538977

• E-mail: dottoressaoaldo@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

have recommended laser ablation (LA) as a possible therapeutic option for the treatment of benign symptomatic thyroid nodules in patients who refuse thyroidectomy, or in those with comorbidities that contraindicate surgery (1). LA tends to be less expensive than thyroidectomy, whether total or partial. LA also does not require hospitalization, and causes only mild and rare adverse events. Thus, it can be undertaken in patients with contraindications for surgery or in those who refuse surgery. Moreover, compared with surgery, minimally invasive procedures for benign thyroid nodules preserve normal thyroid function (2).

Other non-surgical treatments for benign thyroid nodules include other percutaneous techniques, such as ethanol ablation, microwave or radiofrequency, and high-intensity

focused ultrasound (3). LA, radiofrequency ablation (RFA), and ethanol ablation are also utilized for recurrent thyroid cancer (3).

Other non-invasive techniques for reducing benign thyroid nodules are radioiodine with recombinant thyroid-stimulating hormone (TSH) (4) or suppressive levothyroxine (L-T4) therapy (5).

While many studies have reported reductions in treated nodules and improvements in the sense of pressure and in esthetic symptoms (3) after LA, none have described changes in quality of life (QoL). The aim of our study was to therefore evaluate QoL changes in a cohort of patients treated with a single session of LA for benign thyroid nodules.

MATERIALS AND METHODS

We conducted this prospective single-center study at the endocrinology department of IRCSS AOU San Martino University-IST of Genoa (Italy) from September 2014 to September 2015. All patients signed an informed consent form that included a detailed explanation of the LA procedure and its purpose. Our Ethics Committee approved the LA treatment protocol.

Subjects

We evaluated patients with benign thyroid nodules, solid or nearly completely solid (with a liquid component not exceeding 30%), single or clearly detectable in a multinodular goiter, with a view to undergoing percutaneous LA (3). These patients had either refused total or subtotal thyroidectomy, or had comorbidities that contraindicated surgery.

We enrolled 14 patients (12 females and 2 males) aged between 38 and 72 years (mean \pm standard deviation [SD], 55 \pm 10 years) with a single thyroid nodule ($n = 8$, 57%) or a predominant thyroid nodule in a goiter ($n = 6$, 43%).

Table 1. Patients Demographic Data

Males/Females	2/12
Age (years) (mean \pm SD)	55 \pm 10
BMI (kg/m^2) (mean \pm SD)	25 \pm 4
L-T4 therapy (yes/no)	2/12
Time since diagnosis (years) (mean \pm SD)	7 \pm 8
MNG/UNG	6/8
Location of the nodule (right lobe/left lobe)	10/6

BMI = body mass index, L-T4 = levothyroxine, MNG= multinodular goiter, SD = standard deviation, UNG= uninodular goiter

These nodules, which had been discovered 7 \pm 8 years earlier, were located in the right lobe in 10 patients (71%) and in the left lobe in six patients (29%). No patient had undergone ethanol ablation of the nodule or radioiodine therapy. Two patients were on L-T4 replacement therapy for hypothyroidism at a mean dosage of 616 \pm 124 μg /weekly. Table 1 reports on patients' features.

Pre-Ablation Assessment and Protocol

Before performing LA, we excluded contraindications for the procedures, as recommended in the Consensus Statement of the Korean Society of Thyroid Radiology for RFA (6). Before LA, patients underwent the following: a review of clinical data and physical examination; routine blood tests and thyroid function tests (free T3 [f-T3], free T4 [f-T4]; TSH); evaluation of anti-thyroid peroxidase antibodies (TPOAbs), calcitonin, thyroglobulin, electrocardiography; and a phoniatic examination. We evaluated the volume (mL) of the nodule undergoing LA by means of the ellipsoid formula: antero-posterior diameter \times latero-lateral diameter \times crano-caudal diameter in millimeter (mm) \times 0.52 / 1000. We also used this formula to calculate the total volume of each thyroid lobe (7).

Before LA, patients underwent fine needle aspiration of the nodule on two separate occasions, to confirm benignity cytologically (Thy 2 in accordance with the British Thyroid Association (8)). Only patients with a finding of benignity on both occasions underwent LA.

Patients filled out both a symptomatic visual analogic scale (VAS) that rated discomfort in the neck and a 13-scale Thyroid-specific Patient Reported Outcome (ThyPRO) QoL questionnaire validated for patients with thyroid disease (9).

Clinical examinations, assessments of thyroid function and thyroid autoimmunity, and VAS scores were repeated after one week and 1, 3, 6, and 12 months. ThyPRO and ultrasound thyroid volume were evaluated after 1, 3, 6, and 12 months. We performed follow-up ultrasound examinations using a MyLab Five (Esaote®, Genoa, Italy) ultrasound scanner with a 7.5 MHz linear transducer (LA 523, Esaote®). We repeated phoniatic examination if symptoms related to chordal dysmotility appeared after the procedure.

Procedures and Methods

Laser ablation was performed in an out-patient regimen. Antiplatelet and anticoagulant therapies were suspended a week before the procedure. On the day of the procedure, patients were in a state of 8-hour fasting. After placement

of a venous catheter, patients underwent intravenous infusion for over 30 minutes of ketorolac 20 mg (Tora-dol®, Recordati Spa, 10 mg/mL, Milan, Italy) and ranitidine 50 mg (Ranitidina®, 50 mg/5mL, S.A.L.F. Spa, Cenate Sotto, Italy) diluted in 100 mL of 0.9% saline solution. Subsequently, intravenous ketorolac 40 mg (Tora-dol® Recordati Spa, 10 mg/mL) and ranitidine 50 mg (Ranitidina® 50 mg/5 mL, S.A.L.F. Spa) were administered in 500 mL of 0.9% saline for about five hours (during and after LA). In subjects allergic to ketorolac or in patients with moderate-to-severe renal impairment, premedication with intravenous paracetamol (500 mg) (Perfalgan®, 10 mg/mL, 50 mL, Bristol-Myers Squibb Srl, Roma, Italy) was carried out before and during the procedure. We placed patients on an operating table in the supine position with the neck hyperextended. Before LA, we performed a careful US examination to evaluate neck anatomy and ensure preservation of the "danger triangle" during procedures (10). Local anesthesia with 2% lidocaine (Lidocaina Cloridrato®, 20 mg/mL, Monico Spa, Mestre, Italy) was carried out at the puncture site. If the patient did not tolerate pain during ablation, we reduced the power or turned it off for several seconds.

In three patients, we performed percutaneous drainage of cystic intranodular fluid before the procedure. LA was performed in a single session by a single operator. The operator had one year of experience with LA, four years of experience of thyroid RFA, and 22 years of experience with fine-needle aspiration biopsy, by means of 300 µm diameter fibers and a 21-Gauge Chiba-needle (ELESTA®, Calenzano, Italy). Procedures were performed by means of a commercially available US scanner (Echo-laser X4®, Esaote®) equipped with a 7.5 MHz linear transducer (LA 332, Esaote®) with a 1064 µm diode laser unit with a maximum of four laser sources, each with an individual energy emission setting and independent activation.

The operator was positioned at the patient's side and inserted from one to two fibers into the longitudinal length of the nodule, forming a shape matching the ellipsoid of thyroid nodule. The initial energy was delivered at 1200–1800 Joules per fiber with an output power of 2–4 W, starting at one centimeter from the bottom of the lesion. One or two 1-cm pull-backs were programmed to maximize the ablation volume in a single LA session. The number of fibers, their placement, the number of pull-backs and total energy delivered were tailored to the shape and volume of each thyroid nodule, as described by Baek et al. (11). LA lasted 16 ± 2 minutes on average (range: 13–19 minutes),

with a mean delivery of 4459 ± 1525 J (range: 1713–6203 J), one or two fibers (mean 1.7) and one or two pull-backs (mean 1.3). The energy load in J/mL was 340 ± 196 (range: 87–742 J/mL). Light irradiation was continuous, but was suspended in the event of pain or in order to reposition the fibers.

After LA, patients received a compressive bandage and ice to apply to the neck. Patients were allowed a light meal before being discharged in the early afternoon. All subjects received a domiciliary prescription for steroid administration (prednisone 25 mg for three days, 12.5 mg for three days, 6.25 mg for three days) and gastric protection, if not already ongoing.

Laboratory Tests

We measured TSH, f-T3, and f-T4 by ultra-sensitive chemiluminescence immunoassay (Cobas® e602, Roche Diagnostics, Milan, Italy). The normal ranges are: 0.27–4.2 mIU/L for TSH, and 2.76–7.07 pmol/L and 11.97–21.88 pmol/L for f-T3 and f-T4. We evaluated TPOAbs by means of DiaSorin (Saluggia, Italy); we regarded concentrations < 100 mU/L as negative. We measured calcitonin by chemiluminescence immunoassay (DiaSorin); in our laboratory, the normal value is < 10 ng/L. We performed automated complete blood counts using an ADVIA 2120 automated counter (Siemens Healthcare, Milan, Italy); coagulation tests on an automated BCS analyzer (Siemens Healthcare); and biochemical tests for the routine assessment of hepatic and renal function on the fully-automated Cobas® c701 platform (Roche Diagnostics).


Questionnaires

We evaluated the subjective benefits of LA several times during the study through a VAS with a score ranging from 0 (no symptoms/discomfort) to 10 (highest level of symptoms/discomfort). We assessed QoL before the procedure (baseline), and after 1, 3, 6, and 12 months, by means of ThyPRO, a validated questionnaire for thyroid diseases (9), which consists of 13 scales with multiple-choice answers (0 = "none"; 1 = "slight"; 2 = "moderate"; 3 = "severe"; 4 = "very severe"). The ThyPRO scales concern the following aspects: goiter symptoms, hyperthyroid symptoms, hypothyroid symptoms, eye symptoms, tiredness, cognitive problems, anxiety, depression, emotional susceptibility, impaired social life, impaired daily life, impaired sex life, and cosmetic complaints.

We also evaluated a further scale, dubbed "general score."

Table 2. Volume of Nodules and Thyroid (Mean \pm SD) and Volume Reduction Ratio of Nodules and Thyroid at Each Time-Point of Study

Time of Study	Nodule Volume (mL)	Nodule Volume Reduction Ratio (%)	Thyroid Volume (mL)	Thyroid Volume Reduction Ratio (%)
Baseline	19 \pm 14	-	32 \pm 16	-
1st month	11 \pm 9	-42	28 \pm 13	-12
3rd month	9 \pm 10	-57	23 \pm 11	-28
6th month	10 \pm 11	-47	24 \pm 12	-25
12th month	9 \pm 12	-57	24 \pm 13	-25

**Fig. 1. Mean changes (columns) with SD (error bars) in nodule (full columns) and thyroid (empty columns) volume in milliliters (A) and percentage (B).** Significance vs. baseline: *p < 0.05, **p < 0.01. SD = standard deviation

It assesses answers to the question, "In the last 4 weeks, has thyroid disease had a negative effect on your QoL?" Lastly, we considered the mean values of the 13-scale score (9).

Statistical Analysis

We present continuous data as means \pm SD. We analysed all data by the GraphPad Prism for Windows (version 6.0, GraphPad Software, San Diego, CA, USA), by means of a non-parametric test. We assessed correlations between variables by means of the Spearman correlation. A p value < 0.05 indicated significance.

RESULTS

Procedure Effects

On enrolment, the mean volume of the nodules was 19 \pm 14 mL (range: 5–55 mL) and the total gland volume was 32 \pm 16 mL (range: 13–59 mL). Table 2 reports the mean volume of nodules and thyroid at each time-point of the study. Figure 1 reports on the mean volumetric changes at different time-points.

After LA, we found a progressive reduction in nodule volume: -37 \pm 23%, -55 \pm 22%, -53 \pm 25%, -58 \pm 25% at the first, third, sixth and twelfth month, respectively ($p < 0.01$ vs. baseline at the first, third, and sixth month, and $p < 0.05$ at the twelfth month). The percentage reductions in thyroid volume were significant at 3, 6, and 12 months ($p < 0.01$, < 0.05 , < 0.05 , respectively) (Fig. 1). At the 12-month follow-up, we observed a reduction of > 50% in 86% of the patients treated ($p < 0.01$). In two patients (14%), however, LA resulted in a nodule volume reduction of < 20%.

Figure 2 shows a nodule at the baseline of the study (Fig. 2A) and the same nodule 12 months after LA (Fig. 2B).

Changes in Thyroid Parameters

Table 3 depicts the parameters of thyroid function at the baseline and at the various time-points. f-T4, f-T3, thyroglobulin, and TSH levels did not exhibit significant changes (Table 3). None of the patients developed hypothyroidism. None of the subjects on L-T4 therapy on enrolment had to increase the dosage. TPOAbs were positive in 21% of patients ($n = 3$); this percentage was the same at




Fig. 2. Changes in volume of nodule at ultrasound scan at baseline (A, B), 12 months after LA (C, D). Transverse (A, C) and longitudinal images (B, D).

Table 3. Thyroid Function at Each Time-Point of Study (Mean \pm SD)

Time of Study	TSH (mIU/L)	f-T3 (pmol/L)	f-T4 (pmol/L)	Thyroglobulin (μ g/L)
Baseline	1.76 \pm 1.31	5.07 \pm 0.74	14.69 \pm 2.40	104.9 \pm 83.5
1st week	1.33 \pm 0.97	5.24 \pm 0.63	15.30 \pm 1.80	452.2 \pm 658.8
1st month	1.25 \pm 0.85	5.24 \pm 0.55	14.95 \pm 2.28	99.8 \pm 93.7
3rd month	1.28 \pm 1.30	5.42 \pm 0.54	15.37 \pm 2.11	103.9 \pm 228.9
6th month	1.57 \pm 1.29	5.07 \pm 0.72	14.97 \pm 1.71	107.9 \pm 178.0
12th month	1.07 \pm 0.55	5.01 \pm 0.64	15.24 \pm 2.11	73.0 \pm 57.8

f-T3 = free T3, f-T4 = free T4, TSH = thyroid-stimulating hormone

the last evaluation.

Subjective Complaints

During the procedure, four patients (26%) experienced discomfort in the neck, and three patients (21%) experienced pain. Seven patients (50%) did not experience any problems. One week after the procedure, five patients (36%) did not have any problems, four (26%) felt discomfort in the neck, three (21%) felt pain (mean VAS score was 3 ± 2), three (21%) had edema in the neck

and one (7%) had a hematoma. These symptoms did not require any kind of medication and resolved spontaneously during the first month. No patient developed hoarseness, dysphagia, nodule rupture, major bleeding or infections.

The VAS score at the baseline was 5 ± 3 , and was significantly lower at each subsequent evaluation: from the first week after LA until the last evaluation at the twelfth month (Fig. 3). The VAS score improved in 100% of patients.

Table 4 shows the mean score on each ThyPRO scale at

each time-point of the study. The data shows a significant improvement on the scale of "goiter symptoms" from the first month onwards, and on the scale of "general score" from the sixth month onwards. The mean values of the 13 scales also improved significantly from the sixth month onwards (Fig. 4). These improvements persisted over time. By contrast, no significant changes in the other scales were recorded.

DISCUSSION

The present paper reports our preliminary data on the use of a single session of LA to treat 14 benign thyroid nodules in 14 patients recruited over 12 months and followed up for




Fig. 3. Changes in visual analog scale score, with mean score (squares) and SD (error bars). Significance vs. baseline: * $p < 0.05$, ** $p < 0.01$.

12 months.

We used standard procedures recommended by the Korean RFA Guidelines (7, 11), and we performed LA after excluding contraindications.

The mean reduction in the volume of our nodules appears to be similar or slightly lower than those observed in other centers: $58 \pm 25\%$. At 12 months, the mean nodule volume reduction was $-72 \pm 11\%$ in a study by Pacella et al. (12), $-84 \pm 13\%$ in a study by Achille et al. (13), $-59 \pm 22\%$ in a study by Papini et al. (14), $-51 \pm 11\%$ in a study by Døssing et al. (15), and $-70 \pm 16\%$ in a study by Mauri et al. (16).

The mean reduction in the volume of our nodules appears to be similar or slightly lower than that observed after a single session of RFA: $-74 \pm 12\%$ in a study by Mauri et al. (16), $-69 \pm 14\%$ in a study by Cesareo et al. (17), and $77 \pm 3\%$ in a study by Faggiano et al. (18), -79.7% in a study of Baek et al. (19), $-84 \pm 15\%$ in a study of Jeong et al. (20). We achieved more than 50% volume reduction at the 12 months in 86% of nodules. This result is comparable to, or better than, the data presented in a three-year multicenter prospective study (67.3%) (14).

Laser ablation can lead to normalization of TSH in patients with hyperthyroidism with "hot" nodules (21). The literature reports a change in thyroid function (hypothyroidism) in 2% of patients after LA (12). By comparison, in our study that enrolled only euthyroid patients, LA did not lead to significant changes in thyroid function and preserved euthyroidism. This data confirms the safety of this procedure and may prompt percutaneous

Table 4. Thyroid-Specific Patient Reported Outcome Scores (Mean \pm SD) on Each Scale at Each Time-Point of Study

Scales	Baseline	1st month	3rd month	6th month	12th month
Goiter symptoms	23 ± 13	$10 \pm 8^*$	$9 \pm 9^{**}$	$8 \pm 5^{**}$	$7 \pm 4^{**}$
Hyperthyroidism symptoms	13 ± 14	8 ± 14	9 ± 14	8 ± 9	2 ± 3
Hypothyroidism symptoms	9 ± 9	6 ± 6	8 ± 9	9 ± 10	7 ± 4
Eye symptoms	9 ± 9	5 ± 7	6 ± 9	3 ± 5	1 ± 2
Tiredness	34 ± 13	32 ± 13	31 ± 16	26 ± 10	21 ± 5
Cognitive problems	11 ± 13	7 ± 12	13 ± 12	10 ± 8	6 ± 4
Anxiety	17 ± 13	12 ± 11	13 ± 17	18 ± 13	17 ± 7
Depression	26 ± 15	19 ± 12	23 ± 15	17 ± 14	19 ± 9
Emotional susceptibility	20 ± 17	15 ± 13	14 ± 18	12 ± 10	10 ± 4
Impaired social life	3 ± 5	5 ± 9	3 ± 6	0 ± 2	0 ± 0
Impaired daily life	5 ± 10	6 ± 8	4 ± 10	2 ± 4	0 ± 0
Impaired sex life	6 ± 11	4 ± 8	3 ± 6	1 ± 4	3 ± 6
Cosmetic complaints	6 ± 8	6 ± 11	4 ± 8	2 ± 4	1 ± 3
General score	14 ± 19	7 ± 12	4 ± 13	$0 \pm 0^{**}$	$0 \pm 0^*$
Mean values	14 ± 7	10 ± 7	11 ± 9	$9 \pm 5^*$	$7 \pm 1^*$

* $p < 0.05$ vs. baseline, ** $p < 0.01$ vs. baseline




**A****B****C**

Fig. 4. Significant changes in Thyroid-Specific Patient Reported Outcome scale scores, expressed in mean percentages (boxes) and SD (error bars).

A. Goiter symptoms scale. **B.** General score scale. **C.** Mean values.
Significance vs. baseline: * $p < 0.05$, ** $p < 0.01$

techniques to be preferred to surgery, which causes hypothyroidism in 100% of cases after total thyroidectomy and in 22% of cases after hemithyroidectomy (2). In comparison studies between RFA and surgery, there were also no hypothyroidism patients after RFA (22, 23).

Most of our patients did not experience any problems either during or after LA. In our study, adverse events were few and mild; indeed, the main complaints were “discomfort in the neck” and “pain” during and after LA. If these symptoms started after LA, they resolved spontaneously in a few weeks; if they arose during LA, they were alleviated by reducing the energy delivered or turning off the fibers for several seconds. In any case, pain was mild, with the mean VAS score being 3.

Other adverse events in our experience were asymptomatic edema of the neck in one patient and a superficial hematoma in another patient; however, these resolved spontaneously. Our patients did not suffer other major adverse events, such as dysphagia, nodule rupture, pericapsular bleeding, vagal symptoms with bradycardia, or infections, which were reported in 0.5% of cases in a study by Pacella et al. (12) on 1280 nodules treated with LA. In that study, the rate of major complications was lower in patients treated without local anesthesia or with no conscious sedation than in patients managed with local anesthesia and conscious sedation. Conversely, complaints of side effects were more frequent in subjects treated without local anesthesia (12). In our protocol, we did not use conscious sedation, which probably explains why we observed no major complications and few adverse events. In our cohort of patients, we did not administer local subcapsular anesthesia, but subcutaneous tissue anesthesia. Furthermore, we infused analgesic and anti-inflammatory drugs before and during the procedures and prescribed steroids for some days after discharge, in order to minimize complications. While these precautions probably helped to minimize complications, they did not completely alleviate pain and discomfort in the neck.

It should be borne in mind that proximity of the light to the capsule cause pain and discomfort in the neck. If patients complain of these symptoms during the procedure, the patients can thereby help the operator not to exceed the capsule of the treated nodule and minimize adverse events (12). In any case, the complications of LA, and of other minimally invasive procedures, such as RFAs (11), are fewer and milder than those of thyroectomy, whether total or partial. The types and frequencies of

adverse events of thyroid surgery are described in a recent review by a group of Indian surgeons (24). A study by Wang et al. (25) describes the prevalence of complications after conventional and endoscopic thyroidectomies as follows: transient laryngeal nerve palsy in 5.4%, transient hypocalcemia in 3.6%, bleeding in 0.5% and hematoma in 0.5% of cases. Furthermore, discomfort in the neck and chest was reported in 80% of patients on the third day, and pain in the neck and chest in 10% of patients one month after thyroidectomy (25).

Many studies have reported improvements in neck discomfort and esthetic symptoms after LA. In a study by Valcavi et al. (21), neck symptoms improved in 73% of patients, were unchanged in 23%, and worsened in only 4%; esthetic symptoms improved in 71% of patients, were unchanged in 24%, and worsened in 5%. Moreover, in a study by Pacella et al. (12), neck symptoms improved in 10–49% of cases, and esthetic symptoms improved in 8–86% of cases. In addition, in a study by Achille et al. (13), esthetic problems were completely resolved in 87% of treated patients, reduced in 9%, and unchanged in 2%, and pressure symptoms were resolved in 88% of cases. In our study, esthetic complaints were assessed by means of the cosmetic scale of ThyPRO, which revealed no improvement after LA. However, it should be noted that the baseline scores on this scale were very low in all our patients.

Quality of life is defined as a person's perception of his/her position in life, in the context of the culture and system of values in which he or she lives and in relation to his or her objectives, expectations, standards, and concerns (26). In thyroid diseases, besides ThyPRO, QoL is often calculated by means of various questionnaires: the Short Form-36 (27), the SF-12 Health Survey (28), the Hamilton Depressive Scale (29), and the Kellner Symptoms Questionnaire (9, 30).

While the Hamilton Depressive Scale (24-scale multiple-choice questionnaire) and the Kellner Symptoms Questionnaire (92-item questionnaire with Yes/No answers) focus more on the psychological aspects of QoL, the Short Form-36 (11-scale multiple-choice questionnaire), the slimmer SF-12 Heath Survey (12-item multiple-choice questionnaire), and ThyPRO analyze both physical and mental health (9, 27-30). We chose to utilize ThyPRO because it has been validated for thyroid diseases and could therefore provide a more detailed analysis of QoL in patients undergoing thyroid LA. Indeed, the 13 scales of ThyPRO investigate several aspects of life that may be impaired by goiter-related compression symptoms or

discomfort in the neck, by esthetic alterations and by an altered thyroid function (both hypo- and hyper-thyroidism). As of this writing, no literature has reported on changes in QoL in patients treated with LA. However, ThyPRO has been used to assess QoL in numerous benign and malignant thyroid diseases. Regarding the use of questionnaires to evaluate changes in QoL in patients treated with thermal ablation for thyroid nodules, a study by Valcavi et al. (31) reported a significant improvement in QoL. The study assessed QoL using the Physical Component Summary and Mental Component Summary of Short Form-12 after two years of follow-up and in 40 patients treated with RFA for benign thyroid nodules. In the that study, both the Physical Component Summary and the Mental Component Summary significantly improved after one year, and remained stable from year one to year two.

Our group recently published a study on changes in QoL, as assessed by means of ThyPRO after RFA of benign thyroid nodules. In that study, we did not find a significant improvement in ThyPRO scales, except for the "general score," which improved after three months (32). The cause of less improvement of ThyPRO scales in this study (32) was probably induced by low volume reduction: the majority of patients showed less than a 50% volume reduction. Moreover, four patients showed increased nodule volume after RFA. The mean volume reductions of nodule was $-18 \pm 18\%$, $-30 \pm 24\%$ and $-27 \pm 22\%$ after RFA vs. $-37 \pm 23\%$, $-53 \pm 25\%$ and $-58 \pm 25\%$ in LA at 1, 6, and 12 months, respectively, although the features of nodules and inclusion criteria were the same in the two studies. In the present study, scores on the "goiter symptoms" and "general score" scales of the ThyPRO questionnaire showed a significant improvement from the first month and from sixth month onwards, respectively. The mean values of the scores on all 13 scales displayed a significant reduction from the sixth month onwards. In the present study, scores on each of the other scales did not change significantly. This could be due to LA does not affecting thyroid function. Indeed, changes in hyperthyroid symptoms, hypothyroid symptoms, eye symptoms, tiredness, cognitive problems, anxiety, depression and emotional susceptibility scales could be more closely related to changes in thyroid hormonal status.

Our study yielded more short-term data on changes in QoL than that of Valcavi et al. (31). However, our cohort of patients was smaller and follow-up was shorter.

The main limitation of our study is its small population ($n = 14$) and short follow-up. Further studies, especially in

a larger cohort of patients and over several years of follow-up, are necessary in order to confirm or disprove our data.

In conclusion, LA is effective in reducing both nodule volume and neck symptoms. Moreover, the procedure is safe. In comparison to surgery, adverse events are few and mild. LA is well-tolerated by patients and the VAS score improves significantly in all patients. In our cohort of patients, the goiter scale, the general score and the mean value of ThyPRO scores improved significantly a few months after LA for benign non-functioning thyroid nodules.

Acknowledgments

Heartfelt thanks to Professor Claudio Maurizio Pacella for the ability and kindness with which he taught us to perform thyroid laser ablation and thanks to Dr. Bernard Patrick for revising the English of the manuscript.

REFERENCES

1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016;26:1-133
2. Verloop H, Louwerens M, Schoones JW, Kievit J, Smit JW, Dekkers OM. Risk of hypothyroidism following hemithyroidectomy: systematic review and meta-analysis of prognostic studies. *J Clin Endocrinol Metab* 2012;97:2243-2255
3. Papini E, Pacella CM, Misicchi I, Guglielmi R, Bizzarri G2, Døssing H, et al. The advent of ultrasound-guided ablation techniques in nodular thyroid disease: towards a patient-tailored approach. *Best Pract Res Clin Endocrinol Metab* 2014;28:601-618
4. Fast S, Nielsen VE, Bonnema SJ, Hegedüs L. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. *Eur J Endocrinol* 2009;160:517-528
5. Bandeira-Echtler E, Bergerhoff K, Richter B. Levothyroxine or minimally invasive therapies for benign thyroid nodules. *Cochrane Database Syst Rev* 2014 Jun 18;(6):CD004098
6. Shin JH, Baek JH, Chung J, Ha EJ, Kim JH, Lee YH, et al. Ultrasonography diagnosis and imaging-based management of thyroid nodules: Revised Korean society of thyroid radiology consensus statement and recommendations. *Korean J Radiol* 2016;17:370-395
7. Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. *Korean J Radiol* 2012;13:117-125
8. Agarwal A, Kocjan G. FNAC thyroid reporting categories: value of using the British Thyroid Association (Thy 1 to Thy 5) thyroid FNAC reporting guidelines. *Cytopathology* 2009;20:133-134
9. Watt T, Hegedüs L, Groenvold M, Bjørner JB, Rasmussen AK, Bonnema SJ, et al. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. *Eur J Endocrinol* 2010;162:161-167
10. Ha EJ, Baek JH, Lee JH. Ultrasonography-based thyroidal and perithyroidal anatomy and its clinical significance. *Korean J Radiol* 2015;16:749-766
11. Baek JH, Lee JH, Valcavi R, Pacella CM, Rhim H, Na DG. Thermal ablation for benign thyroid nodules: radiofrequency and laser. *Korean J Radiol* 2011;12:525-540
12. Pacella CM, Mauri G, Achille G, Barbaro D, Bizzarri G, De Feo P, et al. Outcomes and risk factors for complications of laser ablation for thyroid nodules: a multicenter study on 1531 patients. *J Clin Endocrinol Metab* 2015;100:3903-3910
13. Achille G, Zizzi S, Di Stasio E, Grammatica A, Grammatica L. Ultrasound-guided percutaneous laser ablation in treating symptomatic solid benign thyroid nodules: Our experience in 45 patients. *Head Neck* 2016;38:677-682
14. Papini E, Rago T, Gambelunghe G, Valcavi R, Bizzarri G, Vitti P, et al. Long-term efficacy of ultrasound-guided laser ablation for benign solid thyroid nodules. Results of a three-year multicenter prospective randomized trial. *J Clin Endocrinol Metab* 2014;99:3653-3659
15. Døssing H, Bennedbæk FN, Hegedüs L. Long-term outcome following interstitial laser photocoagulation of benign cold thyroid nodules. *Eur J Endocrinol* 2011;165:123-128
16. Mauri G, Cova L, Monaco CG, Sconfienza LM, Corbetta S, Benedini S, et al. Benign thyroid nodules treatment using percutaneous laser ablation (PLA) and radiofrequency ablation (RFA). *Int J Hyperthermia* 2016 Nov 15 [Epub ahead of print]. <https://doi.org/10.1080/02656736.2016.1244707>
17. Cesareo R, Pasqualini V, Simeoni C, Sacchi M, Saralli E, Campagna G, et al. Prospective study of effectiveness of ultrasound-guided radiofrequency ablation versus control group in patients affected by benign thyroid nodules. *J Clin Endocrinol Metab* 2015;100:460-466
18. Faggiano A, Ramundo V, Assanti AP, Fonderico F, Macchia PE, Misso C, et al. Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study. *J Clin Endocrinol Metab* 2012;97:4439-4445
19. Baek JH, Kim YS, Lee D, Huh JY, Lee JH. Benign predominantly solid thyroid nodules: prospective study of efficacy of sonographically guided radiofrequency ablation versus control condition. *AJR Am J Roentgenol* 2010;194:1137-1142
20. Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. *Eur Radiol* 2008;18:1244-1250
21. Valcavi R, Riganti F, Bertani A, Formisano D, Pacella CM. Percutaneous laser ablation of cold benign thyroid nodules: a 3-year follow-up study in 122 patients. *Thyroid* 2010;20:1253-

1261

22. Che Y, Jin S, Shi C, Wang L, Zhang X, Li Y, et al. Treatment of benign thyroid nodules: comparison of surgery with radiofrequency ablation. *AJNR Am J Neuroradiol* 2015;36:1321-1325
23. Bernardi S, Dobrinja C, Fabris B, Bazzocchi G, Sabato N, Ulcigrai V, et al. Radiofrequency ablation compared to surgery for the treatment of benign thyroid nodules. *Int J Endocrinol* 2014;2014:934595
24. Padur AA, Kumar N, Guru A, Badagabettu SN, Shanthakumar SR, Virupakshamurthy MB, et al. Safety and effectiveness of total thyroidectomy and its comparison with subtotal thyroidectomy and other thyroid surgeries: a systematic review. *J Thyroid Res* 2016;2016:7594615
25. Wang YC, Zhu JQ, Liu K, Xiong JJ, Xing TF, Han QQ, et al. Surgical outcomes comparison between endoscopic and conventional open thyroidectomy for benign thyroid nodules. *J Craniofac Surg* 2015;26:e714-e718
26. Crevenna R, Zettinig G, Keilani M, Posch M, Schmidinger M, Pirich C, et al. Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapy. *Support Care Cancer* 2003;11:597-603
27. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care* 1993;31:247-263
28. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. *Med Care* 1996;34:220-233
29. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;23:56-62
30. Kellner R. A symptom questionnaire. *J Clin Psychiatry* 1987;48:268-274
31. Valcavi R, Tsamalropoulos P. Health-related quality of life after percutaneous radiofrequency ablation of cold, solid, benign thyroid nodules: a 2-year follow-up study in 40 patients. *Endocr Pract* 2015;21:887-896
32. Oddo S, Felix E, Repetto AM, Mussap M, Giusti M. Quality of life in patients treated with radiofrequency ablation for thyroid nodules. *Res J Endocrinol Metab* 2016 November 1 [Epub]. <http://doi.org/10.7243/2053-3640-4-1>